Yes, Rs 583 Cr was Fy17 revenue, Thats why i said value the remaining business with cash Rs 1500 Cr in the balance sheet.
I am not too excited about Rs 1500Cr investment into R&D, This is what their competitors are already doing from past many years …
In interview he talked about going up into value chain as other big pharma companies are already doing, by that he means going into Biosimilars and Complex generics.
Don’t think Rs15000 Cr will start fetching return immediately, Even if they will be able to make new drugs using it, There are lots of regulatory approvals which take their own time before you can get product into the markets.
I am having hard time evaluating value here, You have already made investment let me know your rationale ? Why you think value should be higher than 3000Cr ?